基于疼痛相关离子通道NaV1.7探讨腕踝针对带状疱疹后神经痛镇痛效应及机制研究

注册号:

Registration number:

ITMCTR2025001389

最近更新日期:

Date of Last Refreshed on:

2025-07-11

注册时间:

Date of Registration:

2025-07-11

注册号状态:

Registration Status:

补注册

Retrospective registration

注册题目:

基于疼痛相关离子通道NaV1.7探讨腕踝针对带状疱疹后神经痛镇痛效应及机制研究

Public title:

Exploring the Analgesic Efficacy and Mechanism of Wrist-Ankle Acupuncture in Postherpetic Neuralgia via Modulation of Pain-Related Ion Channels NaV1.7

注册题目简写:

English Acronym:

研究课题的正式科学名称:

基于疼痛相关离子通道NaV1.7探讨腕踝针对 带状疱疹后神经痛镇痛效应及机制研究

Scientific title:

Exploring the Analgesic Efficacy and Mechanism of Wrist-Ankle Acupuncture in Postherpetic Neuralgia via Modulation of Pain-Related Ion Channels NaV1.7

研究课题的正式科学名称简写:

Scientific title acronym:

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

刘伟群

研究负责人:

刘伟群

Applicant:

Weiqun Liu

Study leader:

Weiqun Liu

申请注册联系人电话:

Applicant telephone:

18065148322

研究负责人电话:

Study leader's telephone:

18065148322

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

1350441369@qq.com

研究负责人电子邮件:

Study leader's E-mail:

1350441369@qq.com

申请单位网址(自愿提供):

Study leader's website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website
(voluntary supply):

申请注册联系人通讯地址:

福建省福州市鼓楼区五四路282号

研究负责人通讯地址:

福建省福州市鼓楼区五四路282号

Applicant address:

No. 282 Wusi Road Gulou District Fuzhou City Fujian Province

Study leader's address:

No. 282 Wusi Road Gulou District Fuzhou City Fujian Province

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

福建中医药大学附属第二人民医院

Applicant's institution:

The Second People's Hospital Affiliated to Fujian University of Traditional Chinese Medicine

是否获伦理委员会批准:

Approved by ethic committee:

伦理委员会批件文号:

Approved No. of ethic committee:

SPHFJP-Y2024089-01

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件

批准本研究的伦理委员会名称:

福建中医药大学附属第二人民医院医学伦理委员会

Name of the ethic committee:

Ethics Committee of the Second People's Hospital Affiliated to Fujian University of Traditional Chinese Medicine

伦理委员会批准日期:

Date of approved by ethic committee:

2024/2/5 0:00:00

伦理委员会联系人:

刘莹莹

Contact Name of the ethic committee:

Yingying Liu

伦理委员会联系地址:

福建省福州市鼓楼区五四路282号

Contact Address of the ethic committee:

No.282 Wusi Road Gulou District Fuzhou Fujian China

伦理委员会联系人电话:

Contact phone of the ethic committee:

15705960157

伦理委员会联系人邮箱:

Contact email of the ethic committee:

sekyllb@163.com

研究实施负责(组长)单位:

福建中医药大学附属第二人民医院

Primary sponsor:

The Second People's Hospital Affiliated to Fujian University of Traditional Chinese Medicine

研究实施负责(组长)单位地址:

福建省福州市鼓楼区五四路282号

Primary sponsor's address:

No. 282 Wusi Road Gulou District Fuzhou City Fujian Province

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

福建省

市(区县):

福州市

Country:

China

Province:

Fujian

City:

Fuzhou

单位(医院):

福建中医药大学附属第二人民医院

具体地址:

福建省福州市鼓楼区五四路282号

Institution
hospital:

The Second People's Hospital Affiliated to Fujian University of Traditional Chinese Medicine

Address:

No. 282 Wusi Road Gulou District Fuzhou City Fujian Province

经费或物资来源:

自筹

Source(s) of funding:

self-raised

研究疾病:

带状疱疹后神经痛

研究疾病代码:

Target disease:

Postherpetic neuralgia

Target disease code:

研究类型:

Study type:

干预性研究

Interventional study

研究设计:

Study design:

随机平行对照

randomized controlled trial(parallel group design)

研究所处阶段:

Study phase:

探索性研究/预试验

Pilot clinical trial

研究目的:

主要目的:证实腕踝针干预在带状疱疹后神经痛(PHN)管理中的安全性及有效性; 次要目的: (1)为PHN的临床治疗提供绿色、安全、有效的干预手段,减少止痛药物的使用,减轻药物治疗带来的不良反应。(2)基于疼痛相关离子通道NaV1.7试图探讨腕踝针镇痛机制,为PHN临床康复提供新的思路和线索。

Objectives of Study:

Main objective: To confirm the safety and efficacy of wrist and ankle needle intervention in the management of postherpetic neuralgia (PHN); Secondary objective: (1) To provide green, safe and effective intervention methods for the clinical treatment of PHN, reduce the use of analgesic drugs, and alleviate the adverse reactions caused by drug treatment. (2) Based on the pain-related ion channel NaV1.7, an attempt was made to explore the analgesic mechanism of wrist and ankle acupuncture, providing new ideas and clues for the clinical rehabilitation of PHN.

药物成份或治疗方案详述:

Description for medicine or protocol of treatment in detail:

纳入标准:

(1)符合PHN的诊断标准,发病部位于胸胁部或腰腹部; (2)年龄50-75岁,性别不限;病程≦12月; (3)4分≦视觉模拟评分法(VAS)评分≦8分; (4)近2周内未针对PHN服用任何药物或采取其他治疗手段;未参加其他正在进行的临床研究; (5)患者同意参与本研究,签署知情同意书,能配合完成各项评估及干预。

Inclusion criteria

(1) Patients meets the diagnostic criteria of PHN and the affected area is located in the thoracic and costal regions or the waist and abdomen. (2) Age 50-75 years old male or female and the disease course is ≤ 12 months; (3) 4 points ≤ Visual Analogue Scale (VAS) score ≤ 8 points; (4) No medication or other treatment methods have been taken for PHN in the past two weeks;Not participating in other ongoing clinical studies; (5) The patient agreed to participate in this study signed the informed consent form and was able to cooperate in completing various evaluations and interventions.

排除标准:

(1)某些特殊类型的带状疱疹者:如会阴部、泛发性带状疱疹等引起的PHN患者; (2)入组前服用相关镇痛药物,不愿意进行洗脱的患者,或在洗脱期或观察期出现严重安全性问题的患者。对PHN进行过神经介入手术或其他神经外科治疗的患者; (3)疼痛区域皮肤有破损者;既往有酰胺类局麻药过敏史者以及对本试验药物过敏者; (4)一个月内使用过糖皮质激素或免疫抑制剂者;其他原因出现的病理性神经痛者(如糖尿病、三叉神经痛等)及癌性疼痛患者; (5)正在服用I类抗心律失常药物(即利多卡因、美西律、苯妥英钠等)的患者; (6)合并全身感染、严重心脏、肝脏、肾脏、血液等系统疾病或恶性肿瘤者;或合并出凝血功能障碍者; (7)精神疾病患者,如重度焦虑、重度抑郁患者;既往有阿片类或安定类药物滥用史者。

Exclusion criteria:

(1) Some special types of herpes zoster patients, such as PHN patients caused by perineum, generalized herpes zoster, etc; (2) Patients who take relevant analgesic drugs before enrollment, are unwilling to undergo elution, or have serious safety issues during elution or observation period. Patients who have undergone nerve intervention surgery or other neurosurgical treatments for PHN; (3) Those with damaged skin in the painful area; Individuals with a history of allergy to amide local anesthetics and those who are allergic to the investigational drug; (4) Individuals who have used glucocorticoids or immunosuppressants within one month; Pathological neuralgia due to other reasons (such as diabetes, trigeminal neuralgia, etc.) and cancer pain patients; (5) Patients currently taking Class I antiarrhythmic drugs (i.e. lidocaine, metoprolol, phenytoin sodium, etc.); (6) Patients with combined systemic infections, severe heart, liver, kidney, blood and other systemic diseases, or malignant tumors; Or combined with coagulation dysfunction; (7) Patients with mental illnesses, such as severe anxiety and depression; Individuals with a history of opioid or tranquilizer drug abuse.

研究实施时间:

Study execute time:

From 2024-02-05

To      2024-12-31

征募观察对象时间:

Recruiting time:

From 2024-02-05

To      2024-12-31

干预措施:

Interventions:

组别:

试验组

样本量:

45

Group:

Test group

Sample size:

干预措施:

腕踝针

干预措施代码:

Intervention:

Wrist-ankle acupuncture

Intervention code:

组别:

对照组

样本量:

45

Group:

Control group

Sample size:

干预措施:

5%利多卡因凝胶贴膏

干预措施代码:

Intervention:

5% lidocaine gel patch

Intervention code:

样本总量 Total sample size : 90

研究实施地点:

Countries of recruitment
and research settings:

国家:

中国

省(直辖市):

福建省

市(区县):

福州市

Country:

China

Province:

Fujian

City:

Fuzhou

单位(医院):

福建中医药大学附属第二人民医院

单位级别:

三级甲等中医院

Institution/hospital:

The Second People's Hospital Affiliated to Fujian University of Traditional Chinese Medicine

Level of the institution:

Tertiary A Hospital of Traditional Chinese Medicine

测量指标:

Outcomes:

指标中文名:

抑郁自评量表

指标类型:

次要指标

Outcome:

Self-rating depression scale

Type:

Secondary indicator

测量时间点:

治疗前、治疗后2周、治疗后4周、随访期4周

测量方法:

量表评估

Measure time point of outcome:

Measure method:

指标中文名:

皮肤病生活质量指数

指标类型:

次要指标

Outcome:

Dermatology life quality index

Type:

Secondary indicator

测量时间点:

治疗前、治疗后2周、治疗后4周、随访期4周

测量方法:

量表评估

Measure time point of outcome:

Measure method:

指标中文名:

视觉模拟评分

指标类型:

主要指标

Outcome:

Visual analogue scale

Type:

Primary indicator

测量时间点:

治疗前、治疗后2周、治疗后4周、随访期4周

测量方法:

量表评估

Measure time point of outcome:

Measure method:

指标中文名:

焦虑自评量表

指标类型:

次要指标

Outcome:

Self-rating anxiety scale

Type:

Secondary indicator

测量时间点:

治疗前、治疗后2周、治疗后4周、随访期4周

测量方法:

量表评估

Measure time point of outcome:

Measure method:

指标中文名:

匹兹堡睡眠质量指数

指标类型:

次要指标

Outcome:

Pittsburgh sleep quality index

Type:

Secondary indicator

测量时间点:

治疗前、治疗后2周、治疗后4周、随访期4周

测量方法:

量表评估

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血液

组织:

Sample Name:

blood

Tissue:

人体标本去向

使用后销毁

说明

Fate of sample 

Destruction after use

Note:

征募研究对象情况:

结束

Completed

年龄范围:

最小 50
Min age years
最大 75
Max age years

Recruiting status:

Participant age:

性别:

Gender:

男女均可

Both

随机方法(请说明由何人用什么方法产生随机序列):

由不参与接诊和评估的医生设置,使用SPSS 29.0软件生成90个随机数,将受试者随机分成试验组和对照组各45例。符合纳入标准的带状疱疹后神经痛患者在签署知情同意书的前提下,按就诊时的顺序随机分配到试验组(腕踝针治疗)和对照组(普瑞巴林治疗)。

Randomization Procedure (please state who generates the random number sequence and by what method):

The subjects were set up by doctors who were not involved in the reception and evaluation. 90 random numbers were generated using SPSS 29.0 software, and the subjects were randomly divided into the experimental group and the control group, with 45 cases in each group. Patients with postherpetic neuralgia who met the inclusion criteria were randomly assigned to the experimental group (treated with wrist and ankle needles) and the control group (treated with pregabalin) in the order of their visit on the premise of signing the informed consent form.

盲法:

本研究无法实施完全的盲法,故采用第三者盲法,保证试验施术者、资料统计者、数据分析者在试验过程中分离。

Blinding:

是否共享原始数据:

IPD sharing:

No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

涉及产权暂不公开

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Property rights are temporarily not disclosed

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

病例记录表

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Case Record Form

数据管理委员会:

Data Managemen Committee:

Yes

研究计划书或研究结果报告发表信息
(杂志名称、期、卷、页,时间;或网址):

Publication information of the protocol/research results report
(name of the journal, volume, issue, pages, time; or website):

国际传统医学临床试验注册平台 京ICP备07032215号-5 提示:推荐使用IE8.0以上版本 宽屏显示分辨率下使用系统